Physician profile
Matthew Crim
NPI 1588993414
$2,644.54
in general payments reported to CMS, 2019-2025
25 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $316 · 2021: $530 · 2022: $512 · 2023: $291 · 2024: $448 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $573.11 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $318.51 | 2019-2024 | Wainua, Farxiga |
| Janssen Pharmaceuticals, INC | $249.01 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $225.25 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.70 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $148.55 | 2019-2021 | |
| Pfizer INC. | $137.16 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $110.17 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.27 | 2019-2025 | Lifevest |
| Irhythm Technologies, INC. | $87.37 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Esperion Therapeutics, INC. | $70.74 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $64.55 | 2021-2024 | Verquvo |
| Edwards Lifesciences Corporation | $59.65 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $51.12 | 2021-2023 | Watchman Access System |
| Akcea Therapeutics, INC. | $47.27 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.14 | 2021-2024 | Wegovy |
| Csl Behring | $37.22 | 2022 | |
| Alnylam Pharmaceuticals INC. | $34.22 | 2019-2024 | Amvuttra |
| Abbott Laboratories | $28.19 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $21.37 | 2024 | Arcalyst |
| Siemens Medical Solutions USA, INC. | $18.24 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.30 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.93 | 2023 | Arcalyst |
| Heartflow, INC. | $14.48 | 2023 | Ffrct |
| Medtronic Vascular, INC. | $13.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Crim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.